The use of CMA activators (such as the RARA antagonist AR7) to improve proteostasis in models of Alzheimer’s disease provides promising preclinical data that CMA activation could be therapeutically beneficial in neurodegenerative disorders. This evidence concerns the gene THRA and early-onset autosomal dominant Alzheimer disease.